Luteinizing Hormone Releasing Hormone

Phase 3Small molecule

Luteinizing Hormone Releasing Hormone is one of 76 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerTerminated

Spinal Cord InjuryActive, not recruiting

Prostate CancerPhase 3

Terminated

Spinal Cord InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

312 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Phase 3

14 2

Acetylsalicylic Acid

Bayer

Phase 3

2 3

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 4

Triptorelin Embonate

Ipsen

Phase 3

3 5

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 6

Fuzuloparib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 7

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT05189457

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Terminated·PProton Collaborative Group·Phase 2/3·NCT01603420·2 enrolled

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05189457·32 enrolled

Spinal Cord Injury1 trial

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

Completed·UUS Department of Veterans Affairs·N/A·NCT00223860·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Luteinizing Hormone Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luteinizing Hormone Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luteinizing Hormone Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUS Department of Veterans Affairs

Luteinizing Hormone Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Prostate Cancer2 trials

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News